Differential Atrial versus Ventricular Activities of Class III Potassium Channel Blockers

This publication has 36 references indexed in Scilit:

• Emerging Class III Antiarrhythmic Agents:Mechanism of Action and Proarrhythmic Potential
  Cardiovascular Drugs and Therapy, 1997
• Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
  The Lancet, 1996
• Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour holter electrocardiography
  Journal of the American College of Cardiology, 1996
• Chemical cardioversion of atrial fibrillation with intravenous dofetilide
  International Journal of Cardiology, 1995
• Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled study
  American Heart Journal, 1995
• The Novel Class III Antiarrhythmics NE-10064 and NE-10133 Inhibit Isk Channels Expressed in Xenopus Oocytes and Iks in Guinea Pig Cardiac Myocytes
  Biochemical and Biophysical Research Communications, 1994
• Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for “reverse use dependent” block
  Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1994
• Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
  Journal of the American College of Cardiology, 1992
• A hyperpolarization-activated inward current in human myocardial cells
  Journal of Molecular and Cellular Cardiology, 1992
• Prolongation of the human cardiac monophasic action potential by sotalol
  The American Journal of Cardiology, 1982